Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Syntara Limited ( (AU:SNT) ) is now available.
Syntara Limited has completed patient recruitment for its randomised, double-blind, placebo-controlled Phase 2 trial of SNT-4728 in isolated REM Sleep Behaviour Disorder (iRBD), a severe sleep disorder affecting around 2% of people over 50 and regarded as a strong clinical predictor of Parkinson’s disease and related neurodegenerative conditions. The multicentre study, run with leading academic partners and backed by Parkinson’s UK’s Parkinson’s Virtual Biotech program in partnership with the Parkinson’s Foundation, is assessing both the safety of SNT-4728 and its ability to reduce neuroinflammation in key brain regions, while also exploring whether it can improve iRBD symptoms; top-line data expected in the second quarter of 2026 will be one of five clinical readouts for Syntara that year and could position the company’s drug as a potential disease-modifying therapy in the prodromal phase of neurodegeneration, bolstering future development and partnering prospects.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited (ASX: SNT) is a clinical-stage drug development company focused on first-in-class, neuro-targeted anti-inflammatory therapies addressing neurological conditions with high unmet medical need, including disorders that precede or are associated with neurodegenerative diseases such as Parkinson’s disease.
Average Trading Volume: 1,456,553
Technical Sentiment Signal: Sell
Current Market Cap: A$50.6M
For an in-depth examination of SNT stock, go to TipRanks’ Overview page.